Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Isabella Fabietti has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Chiara Vassallo

    Fetal and Perinatal Medicine and Surgery Unit, Area of Fetal, Neonatal and Cardiological Sciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

    3 shared publications
  • Laura Valfrè

    Neonatal and Pediatric Surgery Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

    3 shared publications
  • Leonardo Caforio

    Fetal and Perinatal Medicine and Surgery Unit, Area of Fetal, Neonatal and Cardiological Sciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

    3 shared publications
  • Milena Viggiano

    Fetal and Perinatal Medicine and Surgery Unit, Area of Fetal, Neonatal and Cardiological Sciences, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

    3 shared publications
  • Alessandra Boni

    Pneumology and Cystic Fibrosis Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy

    2 shared publications
  • Alessandro Mancini

    Division of Metabolic Diseases and Hepatology, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy

    2 shared publications

Latest Publications

  • Prenatal assessment of diaphragmatic defect size in left-sided congenital diaphragmatic hernia using a novel MRI-based parameter for outcome prediction: the Defect-to-HEmithorax Ratio (DHER)

    by Chiara Panunzi, Sara Savelli, Laura Valfrè, Irma Capolupo, Milena Viggiano, Chiara Vassallo, Andrea Conforti, Leonardo Caforio, Isabella Fabietti

  • Open Access

    Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence

    by Alessandra Boni, Chiara Vassallo, Fabiana Ciciriello, Luca Cristiani, Alessandro Mancini, Luigi Zucaro, Sonia Graziano, Bianca Maria Goffredo, Federico Alghisi, Massimiliano Raponi, et al.

    Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastrointestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Seven relevant studies were identified and qualitatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing confirmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated improvement in bowel dilatation and hyperchogenity. The infant was delivered at 36 + 2, passed meconium spontaneously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence the early trajectory of CF, potentially by preventing MI and potentially delaying the progression to pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.


  • Open Access

    Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Review of the Emerging Evidence

    by Alessandra Boni, Chiara Vassallo, Fabiana Ciciriello, Luca Cristiani, Alessandro Mancini, Luigi Zucaro, Sonia Graziano, Bianca Maria Goffredo, Federico Alghisi, Massimiliano Raponi, et al.

    Introduction: Cystic fibrosis (CF) frequently presents prenatally with meconium ileus (MI), a condition associated with significant neonatal morbidity and long-term gastro-intestinal complications. The advent of highly effective CFTR modulators, particularly elexacaftor/tezacaftor/ivacaftor (ETI), during pregnancy remains off-label, and their role as in-utero therapy for affected fetuses of carrier mothers is still emerging. Methods: We conducted a narrative literature review using PubMed, Embase, and Scopus to identify published reports of in utero CFTR modulator therapy for MI between 2022 and 2026. Ten relevant studies were identified and quali-tatively synthesized. Their findings were interpreted in comparison with the present case. Results: We describe the first Italian case of prenatal ETI therapy for fetal CF. At 32 weeks’ gestation, ultrasound (US) findings were suggestive of evolving MI. Both parents were carriers of F508del CFTR and subsequent testing con-firmed fetal homozygosity. Following urgent multidisciplinary consultation and ethics committee approval, maternal ETI therapy was initiated at 33 weeks’ gestation. After 21 days of treatment, follow-up fetal US demonstrated im-provement in bowel dilatation and hyperchogenity. The infant was delivered at 36 +2, passed meconium spontane-ously, and required no surgical intervention. Pharmacokinetic assessment showed substantial transplacental transfer of all three ETI components, with cord-to-maternal plasma ratios of 0.34 (elexacaftor), 2.48 (tezacaftor), and 0.58 (ivacaftor), and detectable concentrations in amniotic fluid. Postnatally, sweat chloride was elevated, and pancreatic function transitioned from initially preserved to pancreatic insufficiency within the first month of life. Conclusions: This case and literature review suggest that prenatal CFTR modulation may influence early trajectory of CF, potentially by preventing MI and preserve pancreatic insufficiency and potentially reducing later gastrointestinal complications. While evidence remains limited, these findings highlight a potential therapeutic window during fetal life and underscore the need for prospective data collection, structured registries, and harmonized clinical guidance in this evolving field.

  • Strong heart, fit brain. Cardiac impact on brain development in fetuses with congenital diaphragmatic hernia: a prospective cohort study

    by Isabella Fabietti, Chiara Vassallo, Milena Viggiano, Anna Claudia Massolo, Laura Valfrè, Alessia Sala, Lorenza Driul, Pietro Bagolan, Leonardo Caforio, Francesco Morini

    CDH fetuses may present with abnormal brain volume and cerebral fissures. Since cardiac function and size may also be altered, we hypothesized that abnormal cardiac function may contribute to the impaired brain development in these fetuses. The aim of this study is to evaluate whether cardiac dimensions and function correlate with brain development in CDH fetuses. All fetuses with left CDH who underwent ultrasound evaluation of cardiac function and brain development between 2018 and 2023 were included. We analyzed the correlation between cardiac size and function parameters with the parieto-occipital (POF) and Sylvian (SF) fissures and insular depth (ID) in 2 gestational periods (GP). Cardiac and brain anatomical measures were corrected for head circumference, and cardiac function parameters were corrected for estimated fetal weight or GA. Correlations were analyzed using the Pearson test. A p-value <0.05 was considered significant. 24 fetuses with left CDH were included. Between 20 and 24 weeks of gestation, POF, SF, and ID were significantly correlated with aortic flow. Right ventricle E/A was significantly correlated with POF and SF, with a trend toward a correlation with ID, approaching the threshold of significance. In this GP, the ID was also significantly correlated with the left ventricle area, E/A, and E’, S’ and A’. Most correlations were lost in the next GP. Between 20 and 24 weeks of gestation, brain development in fetuses with CDH is significantly correlated with cardiac function. Most of these correlations were lost at 25–28 weeks of gestation. Further studies are needed to confirm our results and to evaluate whether these findings have postnatal clinical significance.

  • Open Access

    Key ultrasound predictors in the prenatal assessment of congenital pulmonary airway malformation: a single-center experience

    by Isabella Fabietti, Alice Novak, Laura Valfrè, Chiara Vassallo, Domenico Umberto De Rose, Milena Viggiano, Andrea Conforti, Chiara Iacusso, Marco Bonito, Pietro Bagolan, et al.

    Background: This study assesses the sensitivity and specificity of congenital pulmonary airway malformation (CPAM) Volume Ratio (CVR) in predicting the need for fetal therapy (FT) and explores the role of additional ultrasound indicators, including the Observed/Expected Lung to Head Ratio (O/E LHR) and Mediastinal Angle Shift (MSA), in improving FT prediction.Methods: We retrospectively studied all CPAM cases referred to our Center from 2018 to 2022. FT was provided at any CVR value in cases of hydrops, rapid lesion growth, or polyhydramnios. The worst CVR, O/E LHR, and MSA values between 20 and 28 weeks of gestation were analyzed.Results: Among 62 CPAM cases, 56.4% right-sided and 43.5% left-sided. Hydrops occurred in 5 cases, all right-sided. FT was required in 14 cases (11 receiving steroids and 3 thoraco-amniotic shunt). CVR was significantly higher in the FT group compared to the non-FT group (p < 0.0001), with an optimal cut-off of 1.25 (Sn 100%; Sp 89.6%) for predicting FT. The O/E LHR was significantly lower in the FT group (mean 44.8 vs. 58.3; p = 0.0046, AUC 0.75), with a Sn of 84% and Sp of 62%. MSA was significantly higher in the FT compared to the non-FT group (p < 0.0001), with a threshold of 13.3° providing high Sn (92.8%) and Sp (89.3%) for predicting FT.Conclusions: CVR is the most reliable predictor of the need for FT, even at lower thresholds. MSA can effectively complement CVR in predicting FT, and using multiple parameters may improve parental counseling and identify cases needing closer monitoring.